May 8, 2019 8:25am

Post reporting Q1/19, many companies lost blood yet, the oversold band aid will soon stem the pricing decline flow

Tuesday’s Q1 reporting includes:  AxoGen (AXGN), Athersys (ATHX) and Sangamo Therapeutics (SGMO)

The 6 W’s: Who, what, where, when, why and what of it … the real question is who is going to report what?


 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

Dow futures are DOWN -0.42% (-109 points), S&P futures are DOWN -0.51% (-14 points) and NASDAQ futures are DOWN -0.59% (-45 points)

 

U.S. stock index futures pointed to a third day of losses; Dow indicates a lower open S&P 500 is down while the NASDAQ is also set to open lower;

European stocks were lower amid escalating fears of a breakdown in trade talks between the U.S. and China;

Asia markets fall amid tariffs fears while Chinese trade data showed exports missed expectations while imports saw a surprise gain;

 

Data docket: U.S. housing market at 7 a.m. ET, when weekly mortgage claims data are released.

 

Henry’omics:

Wednesday’s futures pointed to a third day of losses on fears the U.S. and China would be unable to resolve a dispute over a proposed trade agreement before new tariffs threatened by President Donald Trump are implemented Friday.

It’s a wing and a prayer today and … be prepared to sit-back and watch rather than “play” this market!

From Tuesday’s closing bell post, “flight to avoid the risk following earnings’ mixed expectations.”

  • Last night’s close was negative with an A/DL of 6/36 and 1 flat and 2 acquired;

Upside volume stats … a compelling comparison

  • Tuesday: 2 out of the 6 upside had higher than the 3 month average volume;
  • Monday: 7 out of the 32 upside had higher than the 3 month average volume;

Downside volume stats … lean

  • Tuesday: 10 out of the 36 downside had higher than the 3 month average volume;
  • Monday: 2 out of the 8 downside had higher than the 3 month average volume

Q2/19 so far:

  • In May, there were 3 negative and 2 positive closes;
  • In April, there has been 10 positive and 11 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

 

Tuesday’s Q1 reporting includes:  AxoGen (AXGN), Athersys (ATHX) and Sangamo Therapeutics (SGMO)

Post earnings release:

  • Applied Genetic Technologies (AGTC) reported a net income – having closed down -$0.09 to $4.23 – BUY;
  • bluebird bio (BLUE) closed down -$10.29 to $137.02 - BUY;
  • Regenxbio (RGNX) has a negative -$1.23 or -2.47% aftermarket indication – SELL;
  • Vericel (VCEL) closed down -$1.10 having broken “even” in “street” expectation (in my mind) and announced a “deal” with MediWound Ltd. (MDWD), a severe burn and wound management company – BUY;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.